CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study Primary Prevention of Heart Failure in Women Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y Nuclear Imaging of the Cardiac Sympathetic Nervous System: A Disease-Specific Interpretation in Heart Failure The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Heart Failure Outcomes With Volume-Guided Management SPECT and PET in ischemic heart failure Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure

Review ArticleVolume 74, Issue 5, August 2019

JOURNAL:J Am Coll Cardiol. Article Link

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

DP Leong, JJV McMurray, PG Joseph et al. Keywords: ACE-I; ARB; ARNI; coronary disease; heart failure

ABSTRACT


The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies.